Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Diseases and Immunity, Liver Disease Diagnosis and Treatment, Gallbladder and Bile Duct Disorders, and Pediatric Hepatobiliary Diseases and Treatments.
Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid.
British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis
Implementation of a care bundle improves PBC management
Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care delivery
Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis
Ursodeoxycholic acid and severe COVID-19 outcomes in a cohort study using the OpenSAFELY platform
Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care delivery
Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells.
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls
Corrigendum to 'An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs' [J Hepatol 2021;75(3):572-581].
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs.
FXR inhibition reduces ACE2 expression, SARS-CoV-2 infection and may improve COVID-19 outcome
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study
High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry
Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom
PBC‐10: a short quality of life measure for clinical screening in primary biliary cholangitis
Editorial: rapid assessment of health‐related quality of life in primary biliary cholangitis—no excuse not to ask. Authors' reply
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways